Business
Arbutus Announces Multiple Abstracts Accepted for Oral and Poster Presentations at the EASL 2021 International Liver Congress in June
Conference Call and Webcast to discuss the new data being presented at EASL scheduled for 8:00 AM ET, Monday, June 28, 2021 WARMINSTER, Pa., June 02, 2021
About this update from Arbutus Biopharma Corporation
[{"type":"text","content":"Conference Call and Webcast to discuss the new data being presented at EASL scheduled for 8:00 AM ET, Monday, June 28, 2021 WARMINSTER, Pa., June 02, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that five abstracts have been accepted for presentation at the upcoming International Liver CongressTM (ILC), the Annual Meeting of the European Association for the Study of the Liver (EASL) in June 2021. Arbutus will hold a conference call at 8:00 AM ET, Monday June 28, 2021 to discuss the new data being presented at EASL. The accepted abstracts include two oral presentations, one of which is a late breaker, and three poster presentations. The presentation details and schedules are as follows: Oral Presentations LBO-2764 Title: Repeat dosing of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B results in robust and sustained HBsAg suppression Presenter: Prof. Man-Fung Yuen, D.Sc., M.D., Ph.D., Deputy Head of Department, Chief of Division of Gastroenterology and Hepatology, Master of Lap Chee, University of Hong Kong. Session: Late Breaker June 26, 2021 / 12:00 PM – 1:30 PM CET (6:00 AM – 7:30 AM ET) AB-729 Presentation Time: 1:15 PM CET (7:15 AM ET) OS-595 Title: Preclinical antiviral profile of AB-836, a potent highly selective hepatitis B virus capsid inhibitor Presenter: Dr. Nagraj Mani, Ph.D., Research Fellow, Arbutus Biopharma Corp. Session: Hepatitis B: Novel Therapeutic Approaches Session Date / Time: June 25, 2021 / 2:00 PM – 3:30 PM CET (8:00 AM – 9:30 AM ET) AB-836 Presentation Time: 2:45 PM CET (8:45 AM ET) Presentation available to ILC participants on June 21, 2021 at 10:00 AM CET (4:00 AM ET) Poster Presentations Poster 2823 Title: Inhibition of hepatitis B surface antigen in chronic hepatitis B subjects by RNA interference therapeutic AB-729 is accompanied by upregulation of HBV-specific T cell activation markers Presenter: Dr. Emily Thi, Ph.D., Director, Immunology and Biomarkers, Arbutus Biopharma Corp. Poster available to ILC participants on June 21, 2021 at 10:00 AM CET (4:00 AM ET) Poster 2822 Title: Inhibition of hepatitis B surface antigen by RNA interference t...